ANGLE (AGL) Share Price, News & Analysis

Company Overview

ANGLE plc, a medical diagnostic company, engages in developing cancer diagnostics products in Europe, North America, and the United Kingdom. The company develops and commercializes Parsortix cell separation system, which captures and harvests circulating tumor cells in metastatic breast cancer patient blood; and HyCEAD. ANGLE plc has a partnership agreement with Bio View Ltd to develop a liquid biopsy circulating tumor cell HER2 assay for breast cancer. The company was founded in 1994 and is based in Guildford, the United Kingdom.

Key Stats

• Today's Range: 9.01 to 9.48
• 50-Day Range: 9 to 16.75
• 52-Week Range: 7.11 to 25.13
• Volume: 330,042 shs
• Average Volume: 1.47 million shs
• Market Capitalization: £29.49 million
• P/E Ratio: N/A
• Dividend Yield: 1.12%
• Price Target: GBX 40
• Consensus Rating: Buy

ANGLE Stock Analysis - MarketRank™

ANGLE scored higher than 42% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

ANGLE has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

ANGLE has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of ANGLE is -1.35, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of ANGLE is -1.35, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

ANGLE has a P/B Ratio of 1.00. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for AGL.

Dividend

• Score: 0.8 / 5
• Dividend Strength: Weak

Dividend Yield

ANGLE pays a meaningful dividend of 1.12%, higher than the bottom 25% of all stocks that pay dividends.

Dividend Growth

ANGLE does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Short Interest

There is no current short interest data available for AGL.

News and Social Media

• Score: 1.9 / 5
• News Sentiment: 0.48

News Sentiment

ANGLE has a news sentiment score of 0.48. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.62 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for ANGLE this week, compared to 0 articles on an average week.

Search Interest

Only 1 people have searched for AGL on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, ANGLE insiders have not sold or bought any company stock.

Percentage Held by Insiders

16.18% of the stock of ANGLE is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Only 18.83% of the stock of ANGLE is held by institutions.

AGL Stock Analysis - Frequently Asked Questions

How have AGL shares performed this year?

ANGLE's stock was trading at GBX 10.25 on January 1st, 2025. Since then, AGL shares have decreased by 10.7% and is now trading at GBX 9.15.
View the best growth stocks for 2025 here.

How were ANGLE's earnings last quarter?

ANGLE plc (LON:AGL) announced its earnings results on Thursday, January, 30th. The company reported ($3.33) EPS for the quarter. ANGLE had a negative trailing twelve-month return on equity of 76.01% and a negative net margin of 890.91%.

How do I buy shares of ANGLE?

Shares of AGL stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

What other stocks do shareholders of ANGLE own?

Based on aggregate information from My MarketBeat watchlists, some other companies that ANGLE investors own include ExlService (EXLS), JPMorgan Chase & Co. (JPM), Lockheed Martin (LMT), Philip Morris International (PM), Anglo American (AAL), AbbVie (ABBV) and Asiamet Resources (ARS).

Company Calendar

• Last Earnings: 1/30/2020
• Today: 3/25/2025

Industry, Sector and Symbol

• Stock Exchange: LON
• Sector: Medical
• Industry: Diagnostics & Research
• Sub-Industry: Healthcare
• Current Symbol: LON:AGL
• CIK: N/A
• Web: www.angleplc.com
• Phone: +44-1483-685830
• Fax: N/A
• Employees: 650
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: GBX 40
• High Stock Price Target: GBX 40
• Low Stock Price Target: GBX 40
• Potential Upside/Downside: +322.2%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 1 Analysts

Profitability

• EPS (Most Recent Fiscal Year): GBX (6.76)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: £-21,761,672.20
• Net Margins: -890.91%
• Pretax Margin: N/A
• Return on Equity: -76.01%
• Return on Assets: -29.89%

Debt

• Debt-to-Equity Ratio: 17.22
• Current Ratio: 5.19
• Quick Ratio: 6.18

Sales & Book Value

• Annual Sales: £2.44 million
• Price / Sales: 12.50
• Cash Flow: GBX 1.63 per share
• Price / Cash Flow: 5.80
• Book Value: GBX 9.18 per share
• Price / Book: 1.03

Miscellaneous

• Outstanding Shares: 322,265,904
• Free Float: N/A
• Market Cap: £30.53 million
• Optionable: Not Optionable
• Beta: 0.22